Brefeldin A

Catalog No.S7046

Brefeldin A  Chemical Structure

Molecular Weight(MW): 280.36

Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis. It could also improve the HDR(homology-directed repair) efficiency and be an enhancer of CRISPR-mediated HDR.

Size Price Stock Quantity  
In DMSO USD 80 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

1 Customer Review

  • Cells were treated with brefeldin A or manumycin A, and the resulting supernatant was collected after 48 h for exosomal preparation (lanes 1 and 2), or exosomes obtained from C81 cells were trypsin-treated or freeze/thawed (F/T) and then trypsin-treated (lanes 3 and 4). Lanes 5 and 6, input exosome controls from C81 or CEM cells, respectively. Resulting exosomes were assayed for the presence of Tax by Western blotting.

    J Biol Chem, 2014, 289(32):22284-305.. Brefeldin A purchased from Selleck.

Purity & Quality Control

Choose Selective ATPase Inhibitors

Biological Activity

Description Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis. It could also improve the HDR(homology-directed repair) efficiency and be an enhancer of CRISPR-mediated HDR.
Targets
ATPase (HCT 116) [1]
0.2 μM
In vitro

Brefeldin A is a fungal metabolite and blocks the forward transport between the endoplasmic reticulum and Golgi apparatus, Brefeldin A causes an impaired distribution of the membrane proteins. When HCT 116 human colon cancer cell is treated with Brefeldin A, morphological changes indicating cell differentiation are observed. Brefeldin A exerts its cytotoxic effects mainly by inducing differentiation and apoptosis in tumor cells. [1] The treatment of the strips with 20 μg/mL Brefeldin A for 6 hours completely abolishes the relaxation induced by bradykinin in the presence of 10mM indomethacin and 30 μM L-NOARG. The treatment with 20 μg/mL Brefeldin A substantially abolishes the bradykinin-induced decreases in [Ca2+]i and tension in the range of concentrations between 1 nM and 1 mM. Brefeldin A has no effect on the [Ca2+]i elevation in endothelial cells induced by bradykinin or substance P. [2] Addition of the fungal metabolite Brefeldin A does not affect the spontaneous phospholipid-dependent GTPS binding to myr-rARF1 but totally abolishs the retinal isotonic extract (RIE)-catalyzed exchange, with half-maximal inhibition at 2 μM Brefeldin A. Brefeldin A prevents a wide variety of membrane traffic pathways. Brefeldin A inhibits an ADP-ribosylation factor-specific guanine nucleotide exchange activity present in Golgi membranes or in brain cytosol. The complete prevention by Brefeldin A strongly suggests that the retinal extract contains an ARF-specific guanine nucleotide exchange factor. Retinal isotonic extract (RIE)-catalyzed GTPS release from both ADP-ribosylation factors (ARFs) is only partly inhibited by Brefeldin A, even at 300 μM. [3] Brefeldin A induces fusion of the Golgi apparatus with the ER. Brefeldin A abolishes the inhibitory effect of the CERT inhibitor HPA-12. Brefeldin A treatment, which induces fusion of the Golgi apparatus and the ER, rescues the limonoid-induced prevention of sphingomyelin biosynthesis. BFA treatment of CHO cells causes a 2 to 3 fold increase in sphingomyelin synthesis. [4] Apart from B-CLL cells, Brefeldin A reportedly causes apoptosis in multiple myeloma (U266, NCI-H929), Jurkat, HeLa, leukaemia (HL60, K562, BJAB), colon (HT-29) and prostate, as well as adenoid cystic sarcoma cells. The administration of 25 ng/mL of Brefeldin A completely blocks growth of HF4.9 and HF28RA cells, whereas higher Brefeldin A doses (75 ng/mL) are required to achieve the same effect in HF1A3 cells. Cell proliferation is inhibited within 24 hours in a dose-dependent manner and, depending on the cell line, almost complete cessation of 3H-thymdine incorporation is observed at 50-75 ng/mL of Brefeldin A (26%, 76%, 87% inhibition at 50 ng/ml and 75%, 87%, 92% inhibition at 75 ng/mL for HF1A3, HF4.9 and HF28RA cells respectively. Brefeldin A-induced cell killing is in a dose-dependent manner using YO-PRO 1/PI assay. [5] Brefeldin A could improve the HDR(homology-directed repair) efficiency. It is an enhancer of CRISPR-mediated HDR[6].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
PC12 M{nmZmZ2dmO2aX;uJGF{e2G7 NVLFO5dKOiEQvF2= NEDaRnoyKGh? MkLsbY5pcWKrdIOgeIhmKExvRF;QRUApOjEEoN88UUkucW6mdXPl[EB1emGwc3nlcpQhTVKNMT:yJJBpd3OyaH;yfYxifGmxbtMg NUS0ZlRyOjZ|NkOxPVE>
C2C12 MmnOSpVv[3Srb36gRZN{[Xl? NX\uW|ZiOcLizsznM41t NH;n[nkyyqCq MWnhZo9tcXOqZYOgZ5l1d2urbnWgdoVt\WG|ZTDmdo9uKEN{Q{GyJI16d3S3YnXz Mk\VNlYzQTF{N{m=
MEFs WT NF:x[49HfW6ldHnvckBCe3OjeR?= NIHuW|Q2yqEQvF2= NX7YNoNrOjBibXnu M37LUINifXOnczDy[ZNq\GWwdDDlcpp6dWW|IIP1Z4gh[XNiTlHHWE1ITlBuIITvJIRq\m[3c3WgZoFkcyC2bzD0bIUhTVJ? NX3TOoVCOjZzOU[wNlM>
MEFs VAMP7 KO NFnZN4lHfW6ldHnvckBCe3OjeR?= MV[1xsDPxE1? M1iybVIxKG2rbh?= MnLEZ4F2e2W|IILld4ll\W62IHXufplu\XNic4XjbEBieyCQQVfUMWdHWCxidH:g[Iln\nW|ZTDiZYNsKHSxIITo[UBGWg>? NUTmWVM5OjZzOU[wNlM>
SMCs NIG2d4VHfW6ldHnvckBCe3OjeR?= M1zvUlExyqEEtXevcYw> NXi2ZmZqOC1zMjDo MnXmSG1UVw>? MlPud4hwf3NiYTD0doVv\CC2b4fhdoR{KGFiaHnnbIVzKGOxbnPlcpRz[XSrb36gc4YhfGinIFXSM3NTKG6ndIfvdoshcW5idHjlJJBmemmwdXPs[YFzKGG{ZXJCpC=> NYnh[pJwOjZzN{KwPFA>
SMCs MlLhSpVv[3Srb36gRZN{[Xl? NEHiWpkyOMLiwsXnM41t M17HTVAuOTJiaB?= MUTEUXNQ NWfyOGNY[2G3c3XzJIEhfHKjboPp[Y51KEOjMjxCpJJmdGWjc3Wg[pJwdSC2aHWgSXIwW1MEoB?= NVnJSYMzOjZzN{KwPFA>
HEMC-1 MWTGeY5kfGmxbjDBd5NigQ>? NFX0fIkxNjIEoNM1[{9udA>? MUmyOOKhcA>? MmS2Z4F2e2W|IHGgbIlocGW{IHnubIljcXSxcomg[YZn\WO2IH;uJIV5d2O7dH;zbZMhfGijbjDuc4Nw\GG8b3zl Mn;HNlU6PzJ5NUm=
HUVEC NGDZc4JHfW6ldHnvckBCe3OjeR?= NVL6[mo2OTEEoN88US=> MV[xxsBp NFzpc4xFVVOR NHO5U4Ni[m:uaYPo[ZMhcHmyb4jpZU1qdmS3Y3XkJJJmdGWjc3Wgc4YhSVSSIH\yc40h[XCrY3HsJIFv\CCkYYPvcIF1\XKjbDDzeZJn[WOncx?= MXqyOVk2Pjl6OB?=
HUVEC MnjDSpVv[3Srb36gRZN{[Xl? M1\3UVExyqEQvF2= NYjn[2JqOcLiaB?= NYO4UHdkTE2VTx?= M3\zXIlv[3KnYYPld:KhfGinIH71cYJmeiCjbnSgbY51\W6|aYT5JI9nKG[udX;y[ZNk\W62IHHy[YF{KGW|cHXjbYFtdHliaX6gdIVzcW63Y3zlZZIhe3CjY3W= Mke5NlU6PTZ7OEi=
Caco-2 NILvdlVHfW6ldHnvckBCe3OjeR?= NY\GRnRqOi53IN88US=> NXrtVGl{OzBibXnu NETmfJpifHSnboXheIV{KHSqZTDUS2Yu|rJzLX3l[IlifGWmIHnuZ5Jm[XOnIHnuJHNGWlRiZoXuZ5Rqd25? MkfiNlU6PTR7M{G=
NRK NYDlUGF6TnWwY4Tpc44hSXO|YYm= M3LlflIxOOLChX7nM41t NF;EemM16oDHaB?= MoizSG1UVw>? M1jD[5Jme2O3ZYOgcYl1d3SrYzDwdo9oemW|c3nvci=> NVyxT29IOjV7NEi1PFY>
HeLa NVHaPZQxTnWwY4Tpc44hSXO|YYm= MlPLNlAx6oDHbnevcYw> NGnicmQ{KGh? M2TUcWROW09? MVfpcoR2[2W|IITo[UBienSrZnnjbYFtKGK{ZXHrMZVxKG:oIITo[UBId2ypaTDjc41xdGW6 NUWwU2dlOjV7NEi1PFY>
COS MofoSpVv[3Srb36gRZN{[Xl? NXOwT2xOOSEQvHevcYw> MX[zJIg> M4LjTINwdXCuZYTlcJkh\Gm|cHXyd4V{KHSqZTDBVE0yKHOrZ37hcOKh NV3Gb4Y2OjV7MUW5NFA>
DF1  NYfmRVYyTnWwY4Tpc44hSXO|YYm= M2XyRVHDqM7:TdMg NF\s[5o1QCCq M1fNcWROW09? MWDkbZNx\XK|ZYRCpJRp\SCneH;n[Y5wfXNiQ2PHZYxPSWOWMjDwdo91\Wmw NGfaeZgzPThyN{C1OC=>
nHDFs  NWiwWIY5TnWwY4Tpc44hSXO|YYm= MkW4NeKh|ryPwrC= NH3hd4czyqCq NWDxRmV4eHKndnXueJMhfGinIHHzd4Vu[my7IH;mJIN6fG:|b3zpZ{Bkd2G2IIDyc5RmcW6|IH;ueI8hT2:uZ3mgcYVu[nKjbnXz NVXkPZZrOjV5N{K2NVY>
FRT  M321VGZ2dmO2aX;uJGF{e2G7 MXm1JO69\y:vbB?= Mo\0NuKhcA>? MX\icI9kc3NidILh[oZq[2urbnegeIhzd3WpaDD0bIUhT2:uZ3mgZ49ueGyneDDifUBqdmirYnn0bY5oKEWULYTvMWdwdGerIITyZY5{eG:{dB?= M4DlfVI2PzZ5MUG1
FRT  MoT4SpVv[3Srb36gRZN{[Xl? NH\rd282KM7:Zz;tcC=> NHHTXoczyqCq NWDmeItVeHKndnXueJMhfGinIHnuZ5Jm[XOnIHnuJINt\WG4ZXSg{tEhe3WkdX7peJMhf2inbjDbUoEsZWoEoIfhd{Bz\WS3Y3Xk M4HHNFI2PzZ5MUG1
HepG2  MXrGeY5kfGmxbjDBd5NigQ>? MV:x5qCKyrWPwrC= MXKyOEBp NYnYWYY2TE2VTx?= NULq[VNZ\GWlcnXhd4V{KHSqZTDs[ZZmdCCxZjDQXHIhdVKQQR?= MVGyOVYyPjV7Nx?=
SMCs NYm0NHVuTnWwY4Tpc44hSXO|YYm= NHvZR4ky|rypL33M M{\NNVMhcA>? MoLZZYNkfW23bHH0[ZMhS06SWUKgdJJwfGWrbjDpckB1cGViRWKgZ49ueGG{dH3lcpQh[W6mIH7vJIxwdmencjDjc{1td2OjbHn6[YQhf2m2aDD0bIUhT2:uZ3mgcYFzc2W{wrC= MXiyOVU5QTR{NR?=
OB-6 M4\0bmFxd3C2b4Ppd{BCe3OjeR?= NXv5Z5dwOi55wrFOwG0> NEK1cVg1QCCq MXnpcoR2[2W|IHHwc5B1d3Orcx?= MoPKNlU2OzJ2OEC=
iPSC-CMs  NG\VOoxHfW6ldHnvckBCe3OjeR?= MWq1NFAhdmdxbXy= MYK0PEBp NVS4[G01cW6lcnXhd4V{KHSqZTDpcpRmdnOrdImgc4YhfGinIHjp[4hmeiCvb3LpcIl1gSCOQV3Qd{BifCC2aHWgZ49{fCCxZjD0bIUhdG:5ZYKgcY9jcWyrdImgd5Bm[2mncx?= NVq0bVVKOjV2OEi2OlY>
SP-Nluc NGr6[ItHfW6ldHnvckBCe3OjeR?= M3v5O|UhdWdxbVy= MUC2JIg> Ml7ISG1UV8Li M2[4eoNifXOnczDhckBqdmO{ZXHz[UBqdiC{ZYDvdpRmeiCjY4Tpeol1gSCrbjD0bIUheGG{YYPpeIU> NUn4NpZmOjV|OUK5PVg>
PEXEL-Nluc MoDuSpVv[3Srb36gRZN{[Xl? Mn\zOUBu\y:vTB?= MUG2JIg> NY\F[GhQTE2VT9Mg MnXwZ4F2e2W|IHHuJIlv[3KnYYPlJIlvKHKncH;yeIVzKGGldHn2bZR6KGmwIITo[UBx[XKjc3n0[S=> M1q4[VI2Ozl{OUm4
H1299 M{XtdGZ2dmO2aX;uJGF{e2G7 NFfFZpoyOCEQvHevcYw> NXPsUXdYOjRiaB?= NXXz[XkycW6mdXPld{BifXSxcHjh[5nDqA>? M33VbFI2Ozh6OUew
MDA-MB-231 M2DwPGNmdGxiVnnhZoltcXS7IFHzd4F6 M2r2UFDjiJN3MDFOwIcwdUx? NWn0OFZCPDhiaB?= M1zWWmVEPTEEoE2gNE4xOTZiwsXnM41N NIWyWXUzPTN3NkW2Oy=>
MDA-MB-231 NF\JN3ZCeG:ydH;zbZMhSXO|YYm= M2r1elAvOSEQvHevcWw> NHXzUnM1KGh? MmPKbY5lfWOnczDhdI9xfG:|aYO= MljxNlU{PTZ3Nke=
MDA-MB-231 NVzLemh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{P3e|AvODFxMD6wOUDPxGdxbVy= NGniUFAzPCCq MUTpcoNz\WG|ZYOgeIhmKG[{YXP0bY9vKG:oIIP1Zk1IOSClZXzsJIRm[nKrcx?= MkHmNlU{PTZ3Nke=
MDA-MB-231 MkPoRZBweHSxc3nzJGF{e2G7 NHTEXXExNjB34pETNUDPxGdxbVy= NFrYNoQzPCCq M4r3fYlv\HWlZYOgVGFTWCBqcH;sfUBCTFBvcnnic5NmKHCxbInt[ZJie2VvMTmgZ4xm[X[jZ3W= NGWwNnczPTN3NkW2Oy=>
MDA-MB-231 MVfGeY5kfGmxbjDBd5NigQ>? MYCw5qCUPTBizsznM41N NFrDXHYzPCCq M{XlZ4lvcGmkaYTzJJRp\SCob4LtZZRqd25ib3[gN2Qh[W6mIELEJINwdG:waXXz MUCyOVM2PjV4Nx?=
A172 NF3HNmJHfW6ldHnvckBCe3OjeR?= NEf5O20yOMLizsznM41t M3nMfFTDqGh? M4DQ[mROW00EoB?= Mn;FdoV{fWy2czDpckB1cGVicnX0do9oemGmZTD0doFve3CxcoSgc4Yh\my3b4Lld4NmdnRiZ4LhcpVt\XN? M1vNcVI2OjN7NUC3
KMS-6 MUXGeY5kfGmxbjDBd5NigQ>? NEXxZWgyyqEQvF5CpC=> MnXLNlQhcA>? NVT6dpNr\XiqaXLpeJMhcGGuZjD0bIUhe2WlcnX0bY9vKG:oIHfhcIFvcW5vTFmgZZMh\GmmIITo[UBkd262cn;s NX7s[GtFOjV{MkmxNlY>
MEC NV;Vd3NITnWwY4Tpc44hSXO|YYm= NFLW[nIyKM7:TR?= M1LLTVEvPSCq MmGwZ4F2e2W|IHGg[JJidWG2aXOg[IVkemWjc3WgbY4hfGinIIP1doZi[2ViVlXHSnIz Ml3SNlUzOjh6MUW=
HEK293/hERG Moj6SpVv[3Srb36gRZN{[Xl? M3fPb|ExyqEQvF2= M{XjbVHDqGh? M1fUSJJme3WudIOgbY4h[SC2aX3lMYRmeGWwZHXueEBz\WS3Y4Tpc44hdWG2dYLlJIhGWkdicILveIVqdsLi MmPONlUzOTh2Nkm=
RBE4 M4PmfmFxd3C2b4Ppd{BCe3OjeR?= M1T0SFLDqM7:TR?= NUfofZYyO+LCk{K0xsBp MXzpcoR2[2W|IHHwc5B1d3OrczD0bY1mKGSncHXu[IVvfGy7 MkC3NlUyOjhyMkW=
RBE4 M17j[mZ2dmO2aX;uJGF{e2G7 NV;HWFF[OsLizszN Mnv1N-KBmzJ2wrDo MlPzbY5kemWjc3XzJJRp\SC[QmCxJJBzd3SnaX6gcIV3\Wy|IHHmeIVzKDNiYX7kJFbDqGhib3[geJJm[XSvZX70 NYPMXnZPOjVzMkiwNlU>
RBE4 NVzyO481TnWwY4Tpc44hSXO|YYm= MUGyxsDPxE1? NVjjc206O+LCk{K0xsBp MXvpcoNz\WG|ZYOgZYN1cX[nIHPhd5Bie2VvMUKgbY4h[SC2aX3lMYRmeGWwZHXueEBu[W6wZYNCpC=> M4LFflI2OTJ6MEK1
RBE4 NEXTOXBHfW6ldHnvckBCe3OjeR?= MVuyxsDPxE1? NGHDOWk{6oDVMkVCpIg> NVzvUW5WcW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[gVm9UKHSrbXWt[IVx\W6mZX70cJk> NH\Cd2MzPTF{OECyOS=>
RBE4 M{fKNGZ2dmO2aX;uJGF{e2G7 M1nx[VLDqM7:TR?= NH\DbZk{6oDVMkVCpIg> MnLZbY5lfWOnczDhJIRmdGG7ZXSg[IVxdGW2aX;uJI9nKHSqZTDFVkBE[TJtwrDjc451\W62IHH0JFbDqGhib3[gbY5kfWKjdHnvckB{cWewaX\pZ4FvfGy7 M1vyZ|I2OTJ6MEK1
RBE4 NXHDbWNUTnWwY4Tpc44hSXO|YYm= MknBNuKh|ryP Ml;2N-KBmzJ2wrDo M2PpbIlv\HWlZYOgZY4hd3[ncnzvZYQhd2ZiQ3GyL:KhcW5idHjlJI1qfG:laH;u[JJq[SCrbjD0bIUh\mm{c4SgOuKhcCCxZjDpcoN2[mG2aX;uJEhx6oDLPPMAjVAvODBzKTDieZQhS2F{K9MgcIV3\Wy|IHnuJJRpcXNib4LnZY5mdGynIHTlZ5Jm[XOnZDDh[pRmeiBzMtMgbEBw\iCrbnP1ZoF1cW:w M3L0U|I2OTJ6MEK1
Huh-7  NEDaXlNHfW6ldHnvckBCe3OjeR?= NV3ZN|NxOc7:Zz;tUC=> MnnRN-KBmzJ2wrDo MUnpcoNz\WG|ZYOgeIhmKGyndnXsJI9nKEGSRUGgbY4h[SC2aX3lMYRmeGWwZHXueEBu[W6wZYK= NVjwfHVjOjVyMk[xO|Q>
HepG2  NX;afGx2TnWwY4Tpc44hSXO|YYm= NHn1bYoy|rypL33M MoXaN-KBmzJ2wrDo NXzIZWZocW6lcnXhd4V{KHSqZTDs[ZZmdCCxZjDBVGUyKGmwIHGgeIlu\S2mZYDlcoRmdnRibXHucoVz NIG5[|EzPTB{NkG3OC=>
H838-LKB1 MmPISpVv[3Srb36gRZN{[Xl? NWrmfGlzOzEEoH7nM41t M1zrNlEzNzF6IHi= M{jjTYlv[3KnYYPld{B1cGVicILveIVqdiCuZY\lcJMhd2ZiQnnQxsA> NVfLOJVROjVyMUGwPFI>
H838-KDLKB1  MlPoSpVv[3Srb36gRZN{[Xl? MUezNOKhdmdxbXy= M3;adFEzNzF6IHi= Mki0bY5kemWjc3XzJJRp\SCycn;0[YlvKGyndnXsd{Bw\iCEaWFCpC=> MmruNlUxOTFyOEK=
H838-KDLKB1  MVPGeY5kfGmxbjDBd5NigQ>? MYqzNOKhdmdxbXy= MV6xNk8yQCCq MVPpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCyaH;zdIhwenmuYYTl[EBmUUZ{zsGgLJBpd3OyaH:t[WlHOs7zKR?= M{PobFI2ODFzMEiy
3T3-L1 MUjGeY5kfGmxbjDBd5NigQ>? NUXld3o2PSEQvHevcYw> NWrENI54OzBibXnu M3vGSY1qdWmlczD0bIUh\W[oZXP0d{Bw\iCrboP1cIlvKGGwZDDjZZV{\XNicn;ieZN1KHCqb4PwbI9zgWyjdHnvckBw\iCDa4SgLHNmeiB2N{OpJIFv\CCyaH;zdIhwenmuYYTpc44hd2ZiQWOxOlAhMFSqcjC2OFIh[W6mIGPldkA2QDhr MUCyOFg1Ozh{Nx?=
3T3-L1 NX;nW2l1TnWwY4Tpc44hSXO|YYm= NYrmU2p1PSEQvHevcYw> MmH4N|AhdWmw M2TrRpJm[2GyaYT1cIF1\XNiaX7zeYxqdiCjY4Tpc44hf2m2aDDy[ZNx\WO2IITvJJJm\3WuYYTpcochSWu2IHHjeIl3cXS7IHHu[EBCWzF4MDDwbI9{eGixconsZZRqd25? MYWyOFg1Ozh{Nx?=
3T3-L1 NFv5fXNHfW6ldHnvckBCe3OjeR?= MYS1JO69\y:vbB?= NW\zZ5JmOzBibXnu NXvZRmVm[2G3c3XzJJJmfmW{c3nicIUhemWmaYP0doljfXSrb36gc4YhT0yXVES= MWCyOFg1Ozh{Nx?=
3T3-L1 NEPjRohHfW6ldHnvckBCe3OjeR?= Ml3qOUDPxGdxbXy= NVXsb2pbOcLiaB?= MUPjZZV{\XNicnXkbZN1emmkdYTpc44hd2ZiR1zVWFQh[nW2IH7veEBqdmO{ZXHz[UBqdiCpbIXjc5NmKHWydHHr[S=> M3LsUlI1QDR|OEK3
3T3-L1 NVjIdmlsTnWwY4Tpc44hSXO|YYm= MVO1JO69\y:vbB?= NUfJb5ZnOcLiaB?= M4XIe4NifXOnczDwbI9{eGixconsZZRqd25ib3[geIhmKE[xeF:xJJRz[W6|Y4LpdJRqd25iZnHjeI9z NUC3Xo9SOjR6NEO4Nlc>
HeLa  NYjzXo5wTnWwY4Tpc44hSXO|YYm= NUPWW4VmPSEQvHevcYw> MWizJIg> MUXjZZV{\XNiboXjcIVieiCneHPseZNqd25ib3[geIhmKE[xeF:xJJRz[W6|Y4LpdJRqd25iZnHjeI9zKGGwZDDk[YNz\WG|ZYOgeJJidnOlcnnweIlwdiCxZjDGc5hQOS2{ZXf1cIF1\WRiZ3Xu[ZM> M3eyflI1QDR|OEK3
HEK293 MnzhSpVv[3Srb36gRZN{[Xl? M{Gyc|XDqM7:Zz;tcC=> NY\rV5lkOTMEoHi= NXXjZpQ6[WKxbHnzbIV{KEOPQT3pcoR2[2WmIFPSSWxFOiC|ZXPy[ZRqd25? MVyyOFY5PzR|MR?=
COS-1 MX\GeY5kfGmxbjDBd5NigQ>? M3K1dlUhyrWpL33s NYLBbVc3OjRiaNMg NIrpeYZz\XO2cnnjeJMhdG:lYXzpfoF1cW:wIH;mJG5DKGmwIITo[UBx\XKrboXjcIVieiC{ZXfpc47DqA>? NHv6b4czPDZ5MUe1NS=>
PRP Mk\tSpVv[3Srb36gRZN{[Xl? NGXiRmwyOCEQvF2= M2jNeIFjem:pYYTld{BUTEZvMd8xMY1m\GmjdHXkJGNZS1J5IHX4eIVzdmGuaYrheIlwdsLi M{jCZ|I1PjZ6N{Ww
RAW264.7 M4WxPWFxd3C2b4Ppd{BCe3OjeR?= MVW0JO69VQ>? MkLoOFghcA>? NWLXbVUx[XS2ZX71ZZRmeyC2aHWgbY5pcWKrdHnvckBw\iCxeD3MSGwucW6mdXPl[EBieG:ydH;zbZMh[W6mIITo[UBn[WOrbHn0ZZRqd25ib3[gZ4hwdGW|dHXyc4wh\W[obIX4JIJ6KEGlLXjFMVE5SS2QSEK= MnjpNlQ3OzlyM{K=
MDMs MXvBdI9xfG:|aYOgRZN{[Xl? NXX0eIdtOTEkgJpOwIcwdWx? NEK5W2EyOi9zNTDo MX\pcoR2[2W|IHHwc5B1d3Orcx?= NVjPbYhGOjR3NU[2PVU>
PMHs  MlW3SpVv[3Srb36gRZN{[Xl? NGeycIgyOOLCk{Kw5qCK|rypL33s MVKyOQKBkWh? MnHQSG1UVw>? MmXTbY5lfWOnZDDFVkB{fHKnc4O= NUK4XlNEOjR2MEeyOFI>
PMHs  NEXncHNCeG:ydH;zbZMhSXO|YYm= NHjY[ocyOOLCk{Kw5qCK|rypL33s MljuNlTjiImq NY\5NZF1TE2VTx?= M3m4Rolv[3KnYYPld{Bk\WyuIHTlZZRp MXWyOFQxPzJ2Mh?=
HEK293/tau NHric2pHfW6ldHnvckBCe3OjeR?= NVnkcFRHPSEQvF2= MU[xM|IwPCCq MU\pcoR2[2W|IFfvcIdqKG[{YXft[Y51[XSrb39CpC=> MV:yOFM3QDB6OR?=
HEK293/tau M{fyPGZ2dmO2aX;uJGF{e2G7 M4LRPVUh|ryP MY[zJIg> NGK2V2lqdmS3Y3XzJJRifSCqeYDldpBpd3OyaH;yfYxifGmxbh?= M2DZcFI1OzZ6MEi5
ADF NYrVZ5R1TnWwY4Tpc44hSXO|YYm= NWH4NWNqOTBizszN MXmxOkBp NHjZVldqdmirYnn0d{B1cGViWn7DcFIucW6mdXPl[EB1emGwc3zvZ4F1cW:wIH;mJGNTXA>? NWi0RolbOjR{MkiyN|I>
U373  MUjGeY5kfGmxbjDBd5NigQ>? MXSxNEDPxE1? MYqxOkBp M2L0VolvcGmkaYTzJJRp\SCcblPsNk1qdmS3Y3XkJJRz[W6|bH;jZZRqd25ib3[gR3JV M4nuXFI1OjJ6MkOy
RKO-HIPK2i MWrGeY5kfGmxbjDBd5NigQ>? Mo\6NVAh|ryP MYexOkBp MlXQbY5pcWKrdIOgeIhmKFqwQ3yyMYlv\HWlZXSgeJJidnOub3PheIlwdiCxZjDDVnQ> NGnwXokzPDJ{OEKzNi=>
ADF  NFTy[WNHfW6ldHnvckBCe3OjeR?= MmDWNVAh|ryPwrC= MV:2JIg> NYTIeHhWcW2yYXnyd{B1cGViRFOgZYN1cX[jdHnvci=> M{Xod|I1OjJ6MkOy
Huh7 NY\zZYlSTnWwY4Tpc44hSXO|YYm= MmDjOUDPxGdxbXy= MlfGOEBp M4jB[YFjd2yrc3jld{B1cGVic3XjdoV1cW:wIH;mJEBqdnS{YXPlcIx2dGG{IFHwc2I> M3jpe|I1OTByMUSw
Huh7 Mkj3SpVv[3Srb36gRZN{[Xl? MV61JO69\y:vbB?= MnzmNUBp NFni[nhk[XW|ZYOgZUB{cWewaX\pZ4FvfCCrbnPy[YF{\SCrbjDBdI9DNWO{ZYPj[Y51ew>? MmHFNlQyODBzNEC=
Huh7 NX\0TXd3TnWwY4Tpc44hSXO|YYm= MnHVOgKBmzFywrDu[{9udA>? NUT3So5lOTJiaB?= NHnVO2pqdmO{ZXHz[ZMhSXCxQj3jdoV{[2WwdIOge4l1cG:3dDDpcohq[mm2aX7nJJNm[3KndHnvci=> MnjmNlQyODBzNEC=
BAECs Mln3SpVv[3Srb36gRZN{[Xl? NWPH[pZNPSEQvHevcYw> NHjUVo0xNTRiaB?= NHjRc5hqdmS3Y3XzJJRp\SC{YYDp[EBl\XCqb4PwbI9zgWyjdHnvckBw\iCnTl;TJIF1KFOnckGxO|k> NXH4clZGOjRyOEWyNlU>
Macrophages M3TSZ2Z2dmO2aX;uJGF{e2G7 NHy3SGw4OSEEtV2= MVy2JIg> M4e4dolvcGmkaYTzJIx2dmG|aX6gbY51\XKwYXzpfoF1cW:wwrC= MV2yOFA{QTd2MB?=
Colo 205 NEjSRVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfmNW4xNTVizsznM41N Mn60OFghcA>? NYfOW2dmcW6qaXLpeJMh[2WubDDndo94fGhiaX6gd5V{eGWwc3nvckBkfWy2dYLld{B4cXSqIHHuJIV{fGmvYYTl[EBKSzVyIH;mJJ4yPSCwZz;tUC=> NYTseHhPOjN7N{O5PVY>
Colo 205 MVjGeY5kfGmxbjDBd5NigQ>? NWn5[5hPOC5yMUKtNE4xOjVizsznM41N NGK1bZAyPCCm M{fUNZJm\HWlZYOgeIhmKGOub37v[4VvcWOrdImgc4YhS2:ubzCyNFUhS1OFcx?= NFjhXo0zOzl5M{m5Oi=>
Colo 205 M3HE[GFxd3C2b4Ppd{BCe3OjeR?= NEXCSncxNjFizsznM41N NGK2R4kxNTJ2IHi= Mlj2bY5lfWOnczDhdI9xfG:|aYOgc4YhS2:ubzCyNFUh[2WubIOgbY4he3W|cHXud4lwdiCldXz0eZJmew>? Ml3TNlM6PzN7OU[=
Colo 205 NVS4Zo9VTnWwY4Tpc44hSXO|YYm= NHnJNGIxNjBzNTFOwIcwdUx? NV;PWFZxOjRiaB?= MnLCbY5lfWOnczD0bIUh\XiycnXzd4lwdiCxZjDFVkB{fHKnc4OtdoVt[XSnZDDn[Y5mew>? MlnSNlM6PzN7OU[=
Colo 205 Ml\wSpVv[3Srb36gRZN{[Xl? NY\uSVRXOC5yMUWg{txoN22O MYCyOEBp MkPvbY5pcWKrdIOgeIhmKGGldHn2bZR6KG:oIF3NVJM> NH;5enIzOzl5M{m5Oi=>
IBRS2 MknYSpVv[3Srb36gRZN{[Xl? NXTSOGp{PSEQvHevcYw> M2m1RlAvPSCq NVW2bXZ5TE2VTx?= M3PRXIRqe3K3cITzJJRp\SCHUlfJR{BidmRiR3;s[4nDqA>? NY\m[|BZOjN7NkO1N|Q>
IBRS2 MWLGeY5kfGmxbjDBd5NigQ>? MY[1JO69\y:vbB?= M{POW|AvPSCq NYPRc5pkTE2VTx?= M4nPSIVvcGGwY3XzJGZOTFZiaX7m[YN1cW:w NICyTFAzOzl4M{WzOC=>
HeLa M4rGXGZ2dmO2aX;uJGF{e2G7 M3S2WFIh|ryP MnnqNkBpyqB? M3PuXIF1fGWwdXH0[ZMhfGinIGTOSk1qdmS3Y3XkJJNm[3KndHnvckBw\iCLTD2xOS=> NEj4fpIzOzl3MEi5Ni=>
HFS  M2LVT2Z2dmO2aX;uJGF{e2G7 M{PnTFAuOSEQvHevcYw> M4K3N|I1KGh? MU\HUHRRKGW6cILld5Nqd25icnXhZ4hmeyCjIIDsZZRm[XViYYSgZ49v[2WwdILheIlwdnNiYYOgcI94KGG|IECuNFEhyrWpL33s MViyN|g6PDZ|Mx?=
HFS  NYfYWZFbTnWwY4Tpc44hSXO|YYm= Moj3NE4xOSEEtXevcYw> M3\WTlI1KGh? NGDVc3BqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4Yh\2y7Y3;zdIhqdmexbHnwbYQhe3mwdHjhd4Uh\2WwZYOgZZQhPiCq M1\ZeFI{QDl2NkOz
OVCAR-3 NVywUJk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\DNgKBmzF3wrFOwG3DqA>? NHHQZowzPMLiaB?= M2n4SIlv\HWlZYOgZUBtd3O|IH;mJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHoEoB?= NF\vXVYzOzh{Nkm2OC=>
OVCAR-3 MUnGeY5kfGmxbjDBd5NigQ>? NV:yO29NOeLCk{G1xsDPxE4EoB?= Mnm0NlTDqGh? MUjpcoR2[2W|IH71Z4xm[XJiZHHtZYdm NGC5fnozOzh{Nkm2OC=>
OVCAR-3 M3TwdWFxd3C2b4Ppd{BCe3OjeR?= M3noblEuOTEEoN88US=> MVy0JIg> NYrBboVFcW6mdXPld{B1cGViYXP0bZZifGmxbjDv[kBieG:ydH;zbZMuemWuYYTl[EBxem:2ZXnudy=> M2PlSlI{QDJ4OU[0
OVCAR-3 MVjBdI9xfG:|aYOgRZN{[Xl? NX3xVVVlOTEEoN88US=> NYnZ[|hYOjUEoHi= NXTJ[5B6cW6mdXPld{Bi[3SrdnH0bY9vKG:oIHPhd5Bie2W| NUT2U3ZSOjN6Mk[5OlQ>
OVCAR-3 M4PKfmZ2dmO2aX;uJGF{e2G7 MlW3NgKBmzFywrFOwG0> NELs[oszPMLiaB?= MU\pcoR2[2W|IHTpd5J2eHSrb36gc4YhfGinIH3peI9kcG:wZILpZYwhfHKjboPt[Y1jemGwZTDwc5RmdnSrYXy= NET0bm0zOzh{Nkm2OC=>
OVCAR-3 NF3jWpFHfW6ldHnvckBCe3OjeR?= M{T4ZlHjiJNzMNMg{txO NYfHR4wzOjUEoHi= MmjYbY5lfWOnczDmc5Ju[XSrb36gc4YhemWjY4TpeoUhd3i7Z3XuJJNx\WOrZYO= MmD3NlM5OjZ7NkS=
OVCAR-3 MUfGeY5kfGmxbjDBd5NigQ>? MUex5qCUOTEEoN88US=> NWXGcVhROjUEoHi= MXXpcohq[mm2czDj[YxtKGGmaHXzbY9vKGGwZDDtbYdz[XSrb36= MofDNlM5OjZ7NkS=
MKN45 NXPrbmVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRDBwMECxJO69\y:vbB?= MmLQNlM4QTN|NEK=
LOVO M1O4bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fwb2lEPTB;MD6xNkDPxGdxbXy= Ml;BNlM4QTN|NEK=
A549 NG\VRodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFP4VolKSzVyPUCuNFQh|rypL33s MXqyN|c6OzN2Mh?=
MDA-MB-435 M1X4Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmj6TWM2ODxyLkCwNUDPxGdxbXy= NVnJZ|lLOjN5OUOzOFI>
HepG2 M4e3cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRDBwMECxJO69\y:vbB?= NVPY[VdZOjN5OUOzOFI>
HL-60 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLMU5ZsUUN3MEywMlAxOSEQvHevcYw> NUOwNZZFOjN5OUOzOFI>

... Click to View More Cell Line Experimental Data

Protocol

Cell Research:

[5]

+ Expand
  • Cell lines: Human follicular lymphoma cell lines HF1A3, HF4.9 and HF28RA
  • Concentrations: 0 ng/mL -75 ng/mL
  • Incubation Time: 5 days
  • Method:

    HF1A3, HF4.9 cell viability upon the treatments is tested using double staining of cells with YO-PRO 1/PI and SYTO16/PI probes. To access cell proliferation, cells are treated with 0–100 ng/mL Brefeldin A in complete medium for 20 hours before adding 1 μCi/mL [methyl-3H]-thymidine for additional 4 hours at 37 °C. The incorporated radioactive thymidine is quantified by scintillation counting with Microbeta counter. To examine long-term effects of Brefeldin A treatment, cells are seeded at initial concentration 105 cells/mL and treated with 0-75 ng/mL Brefeldin A for up to 5 days. At the time indicated, a sample of cells is removed and viable cell number is assessed by standard Trypan Blue exclusion assay.


    (Only for Reference)

Solubility (25°C)

In vitro DMSO 4 mg/mL (14.26 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 280.36
Formula

C16H24O4

CAS No. 20350-15-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

ATPase Signaling Pathway Map

Related ATPase Products0

Tags: buy Brefeldin A | Brefeldin A supplier | purchase Brefeldin A | Brefeldin A cost | Brefeldin A manufacturer | order Brefeldin A | Brefeldin A distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID